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Abstract Using genetic and physical assays for protein-protein teractions, we identified a fast isoform of troponin T that binds to dystrophin. 
Troponin T specifically bound to the first of two highly conserved leucine zipper motifs in the carboxy terminus of dystrophin [1,2]. Single amino 
acid changes in the zipper predicted to disrupt a-helix formation or cause steric hindrance abolished this binding. These data support the hypothesis 
that dystrophin couples the contractile apparatus to the sarcolemma nd indicate that leucine zipper mediated protein-protein interactions are 
functionally important in the cytoskeleton as well as the nucleus. 
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1. Introduction 
Duchenne muscular dystrophy is a severe X-linked recessive 
myopathy caused by defects in the gene encoding dystrophin, 
a 427 kDa actin-binding protein [3] that is related in sequence 
and structure to spectrin and a-actinin [4,5]. In skeletal muscle, 
it is associated with the cell membrane (sarcolemma) [6-g]. 
While the precise function of dystrophin is unknown, its ab- 
sence leads to several pathophysiological changes that ulti- 
mately result in profound necrosis. Biochemical studies have 
led to the identification of a dystrophin-glycoprotein complex 
(DGC) that links the sarcolemma and extracellular matrix to 
the carboxy terminus of dystrophin [9,10,11,12]. Interestingly, 
this region of dystrophin contains two leucine zipper motifs 
separated by a 44 amino acid proline rich spacer [2]. The first 
of these motifs is identical in human, mouse, and chicken 
dystrophin and conserved in both torpedo dystrophin and 
utrophin, a dystrophin related protein. The second zipper is 
identical in all of these proteins. As the leucine zipper is a well- 
characterized mediator of protein-protein interactions, we 
hypothesized that they were sites of dystrophin complex assem- 
bly. Using the two-hybrid system [14,16] to probe these interac- 
tions, we identified a novel association between dystrophin and 
a fast isoform of troponin T. Notably, troponin T is the first 
skeletal muscle specific protein demonstrated to bind dystro- 
phin. This physical association suggests a functional link be- 
tween the cell membrane and the contractile apparatus. 
2. Materials and methods 
2.1. Two-hybrid system library construction 
PoIy(A)+ RNA was purified from adult C57BUlOJ mouse hindlimb 
skeletal muscle RNA using Poly A Quik cclumns (Stratagene, LaJolla, 
CA). cDNA was synthesized with SuperScript reverse transcrlptase 
(Gihco/BRL, Gaithersburg, MD) and cloned essentially as described 
in [16], except hat jlACT was digested with XIzoI and a single T filled 
in with the Klenow fragment of DNA polymerase I instead of Taq 
polymerase. 0.2pg of cDNA was ligated to 2pg of vector and packaged 
with Gigapack Gold II (Stratagene, La Jolla, CA). Two million primary 
recombinant plaque forming units (pfus) were obtained. The library 
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was ampliied and excised in plasmid form by in vivo recombination 
in E. coli host BNN132. 
2.2. Yeast plate lijts 
Yeast colonies were grown to approximately 1 mm diameter and 
lifted onto Hybond N &en (Amersham, Buckinghamshire, UK). Fil- 
ters were immersed in liquid nitrogen for 5 s and allowed to dry at room 
temperature, then layered on 0.5 ml of 1 mg/ml 5-bromo4chloro- 
indolyl-@galactoside (X-gal) in Z buffer and incubated for 30-90 min 
at room temperature. Z buffer is 16.1 g Na2HFQ7H,0, 5.5 g 
NaH,PO,.H,O, 0.75 g KCl, 0.25 g MgS04*7H,0, and 2.7 ml/&mercap- 
toethanol per liter [17]. 
2.3. Quantitative /I-galactosiaizse assays 
Dystrophin carboxy terminus encoding fragments were generated by 
the polymerase chain reaction (PCR) and cloned into the EcoRI site of 
pMA424. Constructs have the following extents: DysH,L,L, (aa: 
2,925-3,586); DysH,LA (aa: 2,925-3,520); DysHd& (aa: 2,925- 
3,498); DysI-LL,,&, (aa: 2,925-3,520); DysI-LL-4 (aa: 2,9253,520). 
Transformations were performed with two independent isolates, one of 
which was sequenced in its entirety and translated in vitro. #?-galactosi- 
dase activity is expressed in Miller units [17] and is the average of 
5 independent transformants with standard errors less than 20%. 
2.4. In vitro translation and protein binding assays 
Recombinant dystrophin protein fragments were produced in E. coli 
using the pRSET expression system (Invitrogen, San Diego, CA). Over- 
night cultures were pelleted and resuspended in sonication buffer (50 
mM sodium phosphate pH 8.0, 100 mM Tris-HCl, pH 8.0, 300 mM 
NaCl, 0.2% Triton X-100, lOpg/ml aprotinin, and lOj&nl leupeptin), 
subjected to one freeze-thaw cycle, and son&ted for 1 min at a medium 
setting. Lysates were clarified by centrifugation (10 min, 10,090 x g), 
and the supematants were chromatographed on an NTA-nickel afhnity 
column (Qiagen, Chatsworth, CA). Proteins were eluted with 100 mM 
HEPES pH 7.5 and 50 mM EDTA. Protein concentrations were deter- 
mined quantitatively by the method of Bradford [27) and qualitatively 
by Coomassie blue staining. 2 pg of protein was fractionated on non- 
denaturing 10% polyacrylamide gels containing 0.1% T&on X-100 and 
375 mM TrisHCl pH 8.8 and transferred to nitrocelhtlose. Blots were 
blocked in binding buffer (20 mM HEPES pH 7.5, 150 mM NaCl, 2.5 
mM MgCl,, 1 mM DTT, and 0.1% Triton X-100) supplemented with 
5% non-fat dry milk. To generate probes for for in vitro binding, the 
full-length mouse troponin T and ARBP cDNAs were cloned into 
pRSET C and used to program a TNT rabbit reticulocyte lysate in the 
presence of ‘5S-r.-methionine as described by the vendor (Promega, 
Madison, WI). 1~1 was fractionated by 10% SDS-PAGE and visualized 
by autoradiography. Reticulocyte lysate containing the radiolabelled 
probe was diluted 1: 50 in binding buffer supplemented with 1% milk 
and incubated with the blot overnight at 4°C. Blots were subjected to 
5 ten minute washes in binding buffer and exposed for l-5 h. 
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Fig. 1. (A) Amino-acid sequence comparison of the leucine zipper regions of human (aa: 3,468-3,665), mouse (aa: 3,461-3,658), chicken (aa: 
3,443-3,640), and torpedo dystrophin (aa: 653-850) and the human dystrophin related protein utrophin (aa: 3,225-3,417). Sequences were aligned 
with PILEUP (UWGCG). Boxed regions indicate identical residues. The leucine zippers are delineated by a dark bar above th sequence. The numbers 
over the leucine residues in the zippers correspond to the ridge of leucines depicted in the helical wheel analysis. (B) Helical wheel analysis of the 
two leucine zippers of mouse dystrophin demonstrating the heptad repeat of leucines and the capacity to form a helix. Leucine 1 corresponds to residue 
3,499 of mouse dystrophin. 
3. Results 
The two-hybrid system is based on the modular nature of the 
yeast GAL4 transcription factor. GAL4 consists of two func- 
tional domains, a DNA binding domain in the amino terminus 
and a transactivating domain in the carboxy terminus. When 
physically separated by co-expressing recombinant DNA bind- 
ing domain and recombinant activating domain, the GAL4 
domains no longer function as a transcription factor. However, 
if each domain is fused to a complementary member of a pair 
of interacting proteins, the two functional domains of GAL4 
are brought in physical proximity and transcriptional activity 
can be restored. In this case, the first of the two hybrids, pGAL- 
DysH,L,L, was generated by fusing the GAL4 DNA binding 
domain to a mouse dystrophin cDNA fragment encoding the 
fourth hinge region [15] to the second leucine zipper (amino 
acid residues 2,9253,498). The second hybrid was a mouse 
muscle cDNA library cloned in AACT [ 161 such that the GAL4 
activation domain was fused to each cDNA. pGAL-DysH,L,L, 
and the cDNA library were co-transformed into ~151, a yeast 
reporter strain carrying GALl-1acZ. Two hundred thousand 
yeast transformants were assayed for /I-galactosidase activity 
[16,17], and eight blue colonies were isolated. Activation do- 
main fusion constructs were recovered from these colonies and 
retransformed into ~151 carrying pGAL-DysH,L,L, or a bat- 
tery of unrelated cDNAs fused to the GAL4 DNA binding 
domain. All exhibited B-galactosidase activity only in the pres- 
ence of the dystrophin construct, and all contained the same 
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Fig. 2. (A) In vitro translation products used as probes in the blot 
overlay experiments (parts B and C). Lane 1: troponin T, lane 2: 
ankyrin repeat binding protein (ARBP). (B) Binding of radiolabelled 
troponin T and ARBP to known troponin interacting proteins. 2 lug of 
tropomyosin (TM, lanes 1 and 3) and the troponin complex (TC, lanes 
2 and 4) were fractionated by 10% SDS-PAGE, immobilized on nitro- 
cellullose, and incubated overnight with a 1: 50 dilution of the probes 
shown in part A. Lanes 1 and 2 were probed with fast troponin T; lanes 
3 and 4 with ARBP. (C) Binding of radiolabelled troponin T and ARBP 
to recombinant dystropbin fragments. DysL,L, contains both leucine 
zippers (aa: 3,354-3,678), DysL& contains the first zipper (aa: 3,354 
3,528) and DysA*L, containsthe second zipper (aa: 3,529-3,678). Lanes 
l-3 were probed with anti-gene 10 antibody; lanes 4-6 with “S-1abelled 
troponin T, and lanes 7-9 with 35S-labelled ARBP. 
gene as determined by Southern blotting and restriction map- 
ping. They did not transactivate when genes encoding SNFl, 
cyclin D, ~53, rev, tat, lamin, or a recently isolated ankyrin- 
repeat binding protein (ARBP) (P.A.P., in preparation) were 
substituted for dystrophin or when vector alone was co-trans- 
formed (Table 1). The lamin control is particularly significant 
as lamin dimerizes via a coiled-coil interaction similar to that 
expected of leucine zippers [18]. One of these clones was com- 
pletely sequenced and was 99.2% identical on the amino acid 
level to Rams norvegicus troponin T class IVa alpha. 
To further define this interaction, several hybrid GAL4 
DNA binding domain-dystrophin mutants were constructed 
(Table 1). Transactivation of IacZ by troponin T was unaf- 
fected by deletion of the second zipper or proline-rich spacer, 
but abolished by deletion of both zippers. Further, point muta- 
tions in the first zipper that alter the leucine of the third heptad 
repeat and should disrupt a-helix formation (L15P) or are 
185 
expected to interfere sterically with leucine zipper mediated 
dimerization (L151) also eliminated transactivation (Fig. 1 and 
Table 1). Therefore, troponin T interacts with the first leucine 
zipper in a manner consistent with the formation of a coiled 
coil. 
As further confirmation of these interactions, we employed 
a physical assay based on Western blotting, similar to that used 
previously to demonstrate the association of an SH3 domain 
binding protein, 3BP-1, with c-ubl[19] and to study the assem- 
bly of the Drosophila Shaker potassium channel [20]. To test the 
applicability of the assay, in vitro translated troponin T and 
ankyrin repeat binding protein control were used as probes for 
the troponin complex or tropomyosin immobilized on nitrocel- 
lulose (Fig. 2A). Radiolabelled troponin T but not the control 
probe specifically detected tropomyosin and troponin I and C 
(Fig. 2B). When applied to various recombinant dystrophin 
protein fragments containing one or both zippers, 35S-labelled 
troponin T interacted only when the first leucine zipper was 
present (Fig. 2C, lanes 4 and 5). No signal was detected from 
the second leucine zipper alone or from the negative control 
probe (Fig. 2C, lanes 6-9). 
4. Discussion 
We have presented evidence from two independent methods 
that a leucine zipper mediates the interaction between the 
carboxy terminus of dystrophin and troponin T. These data 
suggest a role in coupling myofilament contraction to the sar- 
colemma, a hypothesis advanced previously based on the obser- 
vation that dystrophin co-localized with the I bands in high 
resolution images of longitudinal muscle sections [21-231. Con- 
sistent with this hypothesis, the most profound defects in mus- 
cle lacking dystrophin are observed in fibers under a heavy 
contractile load. Type IIb fast-twitch fibers, which respond to 
high frequency neuronal stimulation, are preferentially affected 
in DMD, degenerating and regenerating before defects in the 
slow fibers are evident [24]. Moreover, very severe pathological 
changes have been observed in mdx mouse diaphragm relative 
to limb muscle and have been attributed to its higher contractile 
workload [25]. The uncoupling of a dystrophin mediated link 
between the contractile apparatus and the membrane may be 
responsible for the pathological response of the muscle. 
In addition to coupling dystrophin to the contractile appara- 
tus, troponin T may play a role in anchoring dystrophin to the 
cytoskeleton. Indeed, deletion of the actin-binding animo ter- 
minus of dystrophin in vivo results in a paradoxically mild 
phenotype [26]. Troponin T may be providing an alternative 
link between dystrophin and microfilaments. 
To our knowledge, the leucine zipper-mediated interaction 
between two cytoskeletal proteins is novel. While functional 
leucine zippers have been extremely well characterized in nu- 
clear proteins and are important for the formation of various 
transcription factor complexes [l], little importance has been 
attributed to their function in cytoskeletal proteins. The tro- 
ponin T-dystrophin interaction suggests that functional leucine 
zippers are more widespread in the cell than previously 
thought. 
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Table 1 
Transactivation of /%galactosidase by various dystrophin fragments and troponin T in the two-hybrid system. 
pGAL CONSTRUCT STRUCTURE PACT FUSION COLOR S-GALACTOSIDASE 
DYS H&.&b w Troponin T Blue 137 
DYS H4L& @+o 
Troponin T Blue 47 
DYS b@b @m 
Troponin T White 4 
White cl 
DYS Hd-lleb 
@4&I Troponin T 
(z&&I Troponin T White cl 
‘JYS t-&r&b 
DYS t-bt-.&b & ARBP White 4 
DYS H&-b w Vector only White 4 
All dystrophin constructs were co-transformed into ~151 with the GAL4 activating domain fusion indicated. Construct names indicate the extents 
of the dystrophin cDNA inserted (I-L-hinge IV, La-first leucine zipper, Lr,-second zipper, d-deletion, L,-isoleucine substitution in the first leucine 
(residue 3513) of the third heptad repeat, L,-proline substitution of leucine at position 3513). Constructs have the following extents: Dys&L,L, 
(aa: 2925-3586); DysI&Lh, (aa: 2925-3520); DysH&& (aa: 2925-3498); DysH,L&, (aa: 2925-3520); DysH,LR& (aa: 2925-3520). 
for providing the human tissue sections and patient information, and 
the Nucleic Acids Core Facility of the Institute for Molecular Genetics 
for sequencing. Computation was performed at NCBI using the 
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